Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3
Early HEOR Market Access Integration
In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Patient-reported outcomes trends show a clear surge in clinical trials from 2008 to 2023, where usage has doubled in interventional studies, while tools like EQ-5D lead as the top generic instrument, with PROMIS seeing e...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS Integration
Addressing Evidence Gaps in AI Polyp Detection
AI Polyp Detection Gaps persist in colorectal cancer screening, as highlighted by the National Institute for He...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Health as a Strategic Economic Imperative
A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections
Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy
Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy
Sacituzumab govitecan for TNBC represents a major step forward in treating untreated
